Indivior de-lists from LSE for ‘outweighed liquidity’ on Nasdaq
The British pharmaceuticals company said the US exchange offers the ‘most attractive and valuable opportunity set’
The British pharmaceuticals company said the US exchange offers the ‘most attractive and valuable opportunity set’
|
|
Increasing size constraints on small-cap strategies and changes to FCA listing rules have made being public unfeasible
|
|
ETF to track the Morningstar US Dividend Enhanced Select Index
|
|
Fraser Thorne believes London must ‘learn to blow its own trumpet’ to be competitive
|
|
UK IPOs have seen a 16.4% average return so far this year versus a 2.5% gain from the FTSE All-Share index
|
|
FGT’s Madeline Wright says the likes of RELX, Sage and Rightmove will be key beneficiaries
|
|
The British chip designer has shunned a listing in its home market
|
|
In aggregate London listed ETFs booked an £8.3bn net inflow in June
|
|
The deal is due to take place on 21 September
|
|
Rationale for Refinitiv deal looks ‘ever more compelling’
|
|
Star manager’s investment boutique was once the biggest driver of trust’s returns
|
|
Lindsell Train manager remains hopeful Hargreaves Lansdown will improve in 2020
|
|